Jump to Navigation

Schizophrenia

March, 2014 | Vol: 12 Issue: 3

In this issue

Learning Objective

Article

Glutamate’s Role in Schizophrenia

Schizophrenia - The Carlat Psychiatry Report (TCPR)

There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.

Expert Q&A

Beyond Medication: Nonpharmacological Treatments for Schizophrenia

Rachel Loewy, PhD, explores evidence-based psychosocial interventions for schizophrenia: CBT, multifamily group therapy, supported employment, and cognitive remediation.

Research Update

Is Treating Depression Good for the Heart?

Depression is a known risk factor for cardiovascular disease (CVD), but, surprisingly, it’s not known whether effectively treating depression can reduce the risk of a future cardiovascular event in depressed patients without preexisting CVD.

Psychiatric Symptoms, Not Diagnoses, Have Most Effect on Work

Psychiatric disorders account for billions of dollars of costs related to absenteeism, reduced productivity, and treatment each year. Most research in this area has focused on standard DSM diagnoses, but it may be more informative to look instead at psychiatric symptoms, such as insomnia and emotional distress, and their effect on the workplace.

News of Note

Children of Young Moms or Old Dads Most Likely to Develop Psychiatric Disorders

People born to women between the ages of 12 and 19 or to men over the age of 45 are at the greatest risk for developing psychiatric disorders, according to the results of a Danish population-based study of close to three million people born between 1955 and 2006.

Vitamin E May Slow Progress of Alzheimer’s

Recent research published in the Journal of the American Medical Association (JAMA) found that vitamin E slowed functional decline in Alzheimer’s disease better than memantine (Namenda) (Dysken MW et al, JAMA 2014;311(1):33-44).